Subscribe for unlimited access to DynaMed content, CME/CE & MOC credit, and email alerts on content you follow.

Already subscribed? Sign in now

Learn more about CME

Pharmacologic Management of Chronic Asthma in Children

MoreVert
AddCircleOutlineFollow
ShareShare
AddCircleOutlineFollow
Follow
ShareShare
Share

You must be a subscriber to see the full topic content.

  • Related Summaries

  • Overview

  • Principles of stepwise treatment

  • KeyboardArrowRight

    Treatment of children < 5 years old

    • Overview of treatment for children < 5 years old

    • Step 1 treatment for children < 5 years old

    • Step 2 treatment for children < 5 years old

    • Step 3 treatment for children < 5 years old

    • Step 4 treatment for children < 5 years old

    • Step 5 treatment for children < 5 years old

    • Step 6 treatment for children < 5 years old

  • KeyboardArrowRight

    Treatment of children aged 5-11 years

    • Overview of treatment for children aged 5-11 years

    • Step 1 treatment for children aged 5-11 years

    • Step 2 treatment for children aged 5-11 years

    • Step 3 treatment for children aged 5-11 years

    • Step 4 treatment for children aged 5-11 years

    • Step 5 treatment for children aged 5-11 years

    • Step 6 treatment for children aged 5-11 years

  • KeyboardArrowRight

    Specific Treatments

    • Inhaled short-acting beta-2 agonists (SABAs)

    • KeyboardArrowRight

      Inhaled corticosteroids (ICS)

      • Overview of ICS

      • Efficacy of ICS

      • Safety of ICS

    • KeyboardArrowRight

      Long-acting beta-2 agonists (LABAs)

      • Overview of LABAs

      • Efficacy of LABAs

      • KeyboardArrowRight

        Safety of LABAs

        • FDA Warning

        • Adverse events

    • KeyboardArrowRight

      Leukotriene-receptor antagonists (LTRAs)

      • Overview of LTRAs

      • Efficacy of LTRAs

      • Safety of LTRAs

    • KeyboardArrowRight

      Methylxanthines

      • Overview of methylxanthines

      • Efficacy of methylxanthines

      • Safety of methylxanthines

    • KeyboardArrowRight

      Mast cell stabilizers

      • Overview of mast cell stabilizers

      • Efficacy of mast cell stabilizers

    • KeyboardArrowRight

      Systemic corticosteroids

      • Overview of systemic corticosteroids

      • Safety of systemic corticosteroids

    • KeyboardArrowRight

      Immunotherapy

      • Overview of immunotherapy

      • Efficacy of immunotherapy

    • Omalizumab

    • Mepolizumab

    • Antimicrobial agents

  • KeyboardArrowRight

    Quality Improvement

    • Choosing Wisely Italy

  • KeyboardArrowRight

    Guidelines and Resources

    • KeyboardArrowRight

      Guidelines

      • International guidelines

      • United States guidelines

      • United Kingdom guidelines

      • Canadian guidelines

      • European guidelines

      • Asian guidelines

      • Central and South American guidelines

      • Australian and New Zealand guidelines

    • Review articles

  • Patient Information

  • KeyboardArrowRight

    ICD Codes

    • ICD-10 codes

  • KeyboardArrowRight

    References

    • General references used

    • Recommendation grading systems used

    • DynaMed Editorial Process

    • Special acknowledgements

    • How to cite

Topic Editor
Floyd R. Livingston MD
KeyboardArrowDown
Affiliations

Clinical Professor of Pediatrics, University of Central Florida School of Medicine; Florida, United States; Clinical Associate Professor of Pediatrics, The Florida State University College of Medicine; Florida, United States; Division Chief, Pediatric Pulmonary & Sleep Medicine, Nemours Children’s Hospital; Florida, United States

Conflicts of Interest

Dr. Livingston declares no relevant financial conflicts of interest.

Deputy Editor
Scott A. Barron MD, FAAP
KeyboardArrowDown
Affiliations

Deputy Editor of Pediatrics, Dynamed; Massachusetts, United States; Associate Professor of Pediatrics, University of Central Florida College of Medicine; Florida, United States

Conflicts of Interest

Dr. Barron declares no relevant financial conflicts of interest.

CheckCircle

top